Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3
Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.
Read original at benzingaStocks · News reference
8-K filing — INOVIO PHARMACEUTICALS, INC. (INO)
Filed: 2026-07-31 AccNo: 0001193125-26-326785 Size: 684 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 31, 2026, 11:23 AM
- Checked
- Jul 31, 2026, 11:23 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Inovio Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results.
Read original at benzinga8-K filing — INOVIO PHARMACEUTICALS, INC. (INO)
Filed: 2026-08-12 AccNo: 0001055726-26-000024 Size: 271 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarInovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.22) by 68.18 percent. This is a 88.52 percent increase over losses of $(0.61) per share
Read original at benzinga